Pharmacokinetics comparison of two pegylated interferon alfa formulations in healthy volunteers-Reference-Cited by-同舟云学术

Pharmacokinetics comparison of two pegylated interferon alfa formulations in healthy volunteers

Published:2018-01-04 Issue:1 Volume:19 Page:
ISSN:2050-6511
Container-title:BMC Pharmacology and Toxicology
language:en
Short-container-title:BMC Pharmacol Toxicol

Author:

Costa Marisa Boff^ORCID,Picon Paulo Dornelles,Sander Guilherme Becker,Cuni Hugo Nodarse,Silva Carmen Valenzuela,Meireles Rolando Páez,Góes Ana Carolina Magalhães Andrade,Batoreu Nadia Maria,Maia Maria de Lourdes de Sousa,Albuquerque Elizabeth Maciel,Matos Denise Cristina de Souza,Saura Pedro Lopez

Funder

Fio Cruz

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Link

http://link.springer.com/content/pdf/10.1186/s40360-017-0192-z.pdf

Reference23 articles.

1. Qi Y, Chilkoti A. Protein-polymer conjugation-moving beyond PEGylation. Curr Opin Chem Biol. 2015 Oct; 28:181-193. PubMed PMID: 26356631. eng.

2. Zhang X, Wang H, Ma Z, Wu B. Effects of pharmaceutical PEGylation on drug metabolism and its clinical concerns. Expert Opin Drug Metab Toxicol. 2014 Dec; 10(12): 1691-1702. PubMed PMID: 25270687. eng.

3. Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC. et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology. 2001 Aug; 34(2): 395-403. PubMed PMID: 11481625. eng.